感染晚期严重新冠肺炎患者是否应服用奈玛特韦片/利托那韦片组合包装?案例报告

Medicine Advances Pub Date : 2023-03-20 DOI:10.1002/med4.12
Qiang Li, Yibo He, Jin Liu, Xiaozhao Lu, Ziyou Zhou, Yu Kang, Wanying Wu, Jielan Wu, Feng Wang, Yinghao Sun, Wei Wang, Chengyi Hui, Wenting Wei, Miaoyun Wen, Jingjing Chen, Yong Liu
{"title":"感染晚期严重新冠肺炎患者是否应服用奈玛特韦片/利托那韦片组合包装?案例报告","authors":"Qiang Li,&nbsp;Yibo He,&nbsp;Jin Liu,&nbsp;Xiaozhao Lu,&nbsp;Ziyou Zhou,&nbsp;Yu Kang,&nbsp;Wanying Wu,&nbsp;Jielan Wu,&nbsp;Feng Wang,&nbsp;Yinghao Sun,&nbsp;Wei Wang,&nbsp;Chengyi Hui,&nbsp;Wenting Wei,&nbsp;Miaoyun Wen,&nbsp;Jingjing Chen,&nbsp;Yong Liu","doi":"10.1002/med4.12","DOIUrl":null,"url":null,"abstract":"<p>The infection of the coronavirus disease 2019 (COVID-19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we report a practically effective use of Paxlovid compensatively in patients with COVID-19 and severe pneumonia after 5 days of infection in a typical case in China. In this case, a 75-year-old man was diagnosed with severe COVID-19 complicated with a pulmonary bacterial infection. After treatment with oxygen inhalation, Cefoperazone-sulbactam and ambroxol, fever and upper respiratory symptoms were alleviated, except for the Oxygenation index (OI) remaining worse, Coronavirus was detected as positive, and levels of interleukin-6 remained high. Paxlovid was prescribed for 5 days subsequently though it was 14 days since symptom onset. Thereafter, the nucleic acid of the patient turned negative in 7 days and the symptoms resolved. This case showed that Paxlovid can be considered in patients with COVID-19 and severe pneumonia even in the later course of infection in clinical practice in China.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.12","citationCount":"0","resultStr":"{\"title\":\"Should Paxlovid be prescribed for patients with severe COVID-19 in the late course of infection? A case report\",\"authors\":\"Qiang Li,&nbsp;Yibo He,&nbsp;Jin Liu,&nbsp;Xiaozhao Lu,&nbsp;Ziyou Zhou,&nbsp;Yu Kang,&nbsp;Wanying Wu,&nbsp;Jielan Wu,&nbsp;Feng Wang,&nbsp;Yinghao Sun,&nbsp;Wei Wang,&nbsp;Chengyi Hui,&nbsp;Wenting Wei,&nbsp;Miaoyun Wen,&nbsp;Jingjing Chen,&nbsp;Yong Liu\",\"doi\":\"10.1002/med4.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The infection of the coronavirus disease 2019 (COVID-19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we report a practically effective use of Paxlovid compensatively in patients with COVID-19 and severe pneumonia after 5 days of infection in a typical case in China. In this case, a 75-year-old man was diagnosed with severe COVID-19 complicated with a pulmonary bacterial infection. After treatment with oxygen inhalation, Cefoperazone-sulbactam and ambroxol, fever and upper respiratory symptoms were alleviated, except for the Oxygenation index (OI) remaining worse, Coronavirus was detected as positive, and levels of interleukin-6 remained high. Paxlovid was prescribed for 5 days subsequently though it was 14 days since symptom onset. Thereafter, the nucleic acid of the patient turned negative in 7 days and the symptoms resolved. This case showed that Paxlovid can be considered in patients with COVID-19 and severe pneumonia even in the later course of infection in clinical practice in China.</p>\",\"PeriodicalId\":100913,\"journal\":{\"name\":\"Medicine Advances\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.12\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine Advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/med4.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine Advances","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/med4.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

2019冠状病毒病(新冠肺炎)的感染通常伴有肺炎,发病率和死亡率都很高。奈玛特韦片/利托那韦片组合包装通常用于症状出现后5天内的轻度和正常肺炎患者。在此,我们报告了奈玛特韦片/利托那韦片组合包装在中国一例典型病例中对新冠肺炎和感染5天后的重症肺炎患者的实际有效补偿使用。在这种情况下,一名75岁的男子被诊断为严重的新冠肺炎合并肺部细菌感染。经吸氧、头孢哌酮舒巴坦和氨溴索治疗后,发烧和上呼吸道症状有所缓解,但氧合指数(OI)仍较低,冠状病毒检测呈阳性,白细胞介素-6水平仍较高。奈玛特韦片/利托那韦片组合包装随后被开了5天的处方,尽管症状出现后14天。此后,患者的核酸在7天内转为阴性,症状消失。该病例表明,在中国临床实践中,即使在感染后期,奈玛特韦片/利托那韦片组合包装也可以用于新冠肺炎和重症肺炎患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Should Paxlovid be prescribed for patients with severe COVID-19 in the late course of infection? A case report

Should Paxlovid be prescribed for patients with severe COVID-19 in the late course of infection? A case report

The infection of the coronavirus disease 2019 (COVID-19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we report a practically effective use of Paxlovid compensatively in patients with COVID-19 and severe pneumonia after 5 days of infection in a typical case in China. In this case, a 75-year-old man was diagnosed with severe COVID-19 complicated with a pulmonary bacterial infection. After treatment with oxygen inhalation, Cefoperazone-sulbactam and ambroxol, fever and upper respiratory symptoms were alleviated, except for the Oxygenation index (OI) remaining worse, Coronavirus was detected as positive, and levels of interleukin-6 remained high. Paxlovid was prescribed for 5 days subsequently though it was 14 days since symptom onset. Thereafter, the nucleic acid of the patient turned negative in 7 days and the symptoms resolved. This case showed that Paxlovid can be considered in patients with COVID-19 and severe pneumonia even in the later course of infection in clinical practice in China.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信